GLPBio

ALC-0315

Catalog No.: GC19792Purity:>98.00%

ALC-0315 هو مكون رئيسي في لقاح COVID‐19mRNA وهو دهن يُبحث عنه بشدة في أبحاث العلاجات النووية الأساسية.

المنتجات مخصصة للاستخدام البحثي فقط، وليست للاستخدام البشري. نحن لا نبيع للمرضى.


ALC-0315
Cas No.: 2036272-55-4
10mgIn Stock
$67.00
1
25mgIn Stock
$133.00
1
50mgIn Stock
$210.00
1
100mgIn Stock
$336.00
1

المراجع (Citations)

لا تتوفر حاليًا مراجع لهذا المنتج. فيما يلي مجموعة مختارة من المنشورات التي تستشهد بمنتجات GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

الوصف (Description)

ALC-0315 is a key component of the COVID‐19mRNA vaccine and a highly sought-after lipid for nucleic acid therapeutics research [1]. Ionizable cationic lipids are essential for efficient in vivo delivery of RNA by lipid nanoparticles (LNPs). DLin-MC3-DMA (MC3), ALC-0315, and SM-102 are the only ionizable cationic lipids currently clinically approved for RNA therapies. ALC-0315 and SM-102 are structurally similar lipids used in SARS-CoV-2 mRNA vaccines [2].

Cationic lipids (CLs) and ionizable lipids (ILs) initiate the first step of self-assembly via electrostatic interactions. because of toxicity issues and lack of in vivo efficacy, CLs have been replaced by pH-sensitive ILs. The overall architecture of CLs and ILs can be broken down into three parts: (1) the headgroup, (2) the linker, and (3) the tails. The headgroups of ALC-0315 contain a terminal hydroxyl group which could decrease the hydration of the headgroup and improve hydrogen-bonding interactions with the nucleic acid, potentially leading to improved transfection ability. The linker typically connects the headgroup with the tails, although the linkers may also be buried within the tails. DLin-MC3-DMA, ALC-0315, and SM-102 all have ester linkers. DLin-MC3-DMA has two linoleyl tails, while ALC-0315 and SM-102 contain two branched saturated tails that are postulated to endow a cone-shaped geometry, facilitating destabilization of the endosomal membrane and cytosolic release of the nucleic acid [3].

References:
[1]. Saadati F, Cammarone S, Ciufolini M A. A Route to Lipid ALC‐0315: a Key Component of a COVID‐19 mRNA Vaccine[J]. Chemistry–A European Journal, 2022, 28(48): e202200906.
[2]. Ferraresso F, Strilchuk A W, Juang L J, et al. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells[J]. Molecular Pharmaceutics, 2022.
[3]. Eygeris Y, Gupta M, Kim J, et al. Chemistry of lipid nanoparticles for RNA delivery[J]. Accounts of Chemical Research, 2021, 55(1): 2-12.

البروتوكول (Protocol)

siRNA–LNP Formulation and Analysis [1]:

Preparation Method

siRNAs were dissolved in sodium acetate (pH 4) and combined with a lipid solution at an amine-to-phosphate (N/P) ratio of 3. The lipid formulations consisted of DSPC, cholesterol, and PEG-DMG at a 10:38.5:1.5% molar ratio, with either 50% DLin-MC3-DMA or ALC-0315. The LNPs were dialyzed against phosphate-buffered saline (PBS) at pH 7.4 in 500-fold excess. For quality control, cholesterol content was measured using the Cholesterol E Assay Kit. To determine siRNA concentration and entrapment, a RiboGreen assay was used. Encapsulation efficiency was measured by comparing Ribogreen signal in LNP samples with or without Triton X-100 detergent. Particle size was measured using a Malvern-Zetasizer Nano.

Animal experiment [2]:

Animal models

C57BL/6J mice

Preparation Method

2′-O-Methylated siRNA targeting murine FVII (siFVII), ADAMTS13 (siADAMTS13) and a negative control siRNA targeting luciferase (siLuc) were used. The resulting LNPs were diluted to a final concentration of 0.1 mg/mL siRNA in PBS prior to intravenous (IV) injection. Injected mice with 1 mg siRNA per kg body weight (mg/kg) for knockdown studies and 5 mg/kg dose for toxicity studies.

Dosage form

1, 5 mg/kg

Applications

Mice treated with siADAMTS13-ALC-0315 at the same dose had greater ADAMTS13mRNA and protein knockdown, compared to mice treated with siADAMTS13-MC3.

References:

[1] : Ferraresso F, Strilchuk A W, Juang L J, et al. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells[J]. Molecular Pharmaceutics, 2022.

وثائق المنتج (Product Documents)

Purity:>98.00%Appearance:A liquid

الخصائص الكيميائية (Chemical Properties)

رقم CAS
2036272-55-4
SMILES
OCCCCN(CCCCCCOC(C(CCCCCC)CCCCCCCC)=O)CCCCCCOC(C(CCCCCC)CCCCCCCC)=O
الصيغة الجزيئية
C48H95NO5
الوزن الجزيئي
766.27
الذوبانية
DMSO : 100 mg/mL (130.50 mM) Ethanol : 100 mg/mL (130.50 mM)
التخزين
4°C, protect from light
إرشادات عامة
اختر مذيبًا مناسبًا وفقًا لبيانات ذوبانية المنتج. بعد التحضير، قسّم المحلول المخزون إلى أجزاء لتجنب دورات التجميد والذوبان المتكررة.
استخدم المحاليل المخزونة خلال 6 أشهر عند حفظها في -80°C، أو خلال شهر واحد عند حفظها في -20°C.
لتحسين الذوبانية، سخّن الأنبوب إلى 37°C وعرّضه للموجات فوق الصوتية لمدة مناسبة.
شروط الشحن
تُشحن عينات التقييم مع عبوات تبريد. وتُشحن الأحجام الأخرى المتاحة في درجة حرارة الغرفة، أو مع عبوات تبريد عند الطلب.

الحاسبات (Calculators)المولارية / التخفيف / الوزن الجزيئي / تحويل الوحدات / تركيبة داخل الجسم الحي / الذوبانية

g/mol

Reviews

Review for ALC-0315

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%